Difficulty: Medium
Average Score: 84%
Practice
The nurse is caring for a child with Kawasaki disease. A student nurse who is on the unit asks if there are medications to treat the disease. The nurseÔÇÖs best response to the student nurse is:
Correct answer
C
Rationale
In treating Kawasaki disease, the correct answer is C) Immunoglobulin G and aspirin. Immunoglobulin G helps to reduce the risk of coronary artery abnormalities associated with Kawasaki disease, while aspirin is used to manage inflammation and reduce the risk of blood clot formation.
Option A) Immunoglobulin G and ACE inhibitors is incorrect because ACE inhibitors are not typically used in the treatment of Kawasaki disease. Option B) Immunoglobulin and heparin is incorrect because heparin is not a standard treatment for Kawasaki disease.
Option D) Immunoglobulin and ibuprofen is incorrect because ibuprofen is not recommended in Kawasaki disease treatment due to its potential to worsen the risk of coronary artery aneurysms.
In an educational context, it is crucial for nursing students to understand the rationale behind treatment choices for pediatric cardiovascular disorders like Kawasaki disease. This knowledge helps ensure safe and effective care for pediatric patients, highlighting the importance of evidence-based practice in pediatric pharmacology.
Option A) Immunoglobulin G and ACE inhibitors is incorrect because ACE inhibitors are not typically used in the treatment of Kawasaki disease. Option B) Immunoglobulin and heparin is incorrect because heparin is not a standard treatment for Kawasaki disease.
Option D) Immunoglobulin and ibuprofen is incorrect because ibuprofen is not recommended in Kawasaki disease treatment due to its potential to worsen the risk of coronary artery aneurysms.
In an educational context, it is crucial for nursing students to understand the rationale behind treatment choices for pediatric cardiovascular disorders like Kawasaki disease. This knowledge helps ensure safe and effective care for pediatric patients, highlighting the importance of evidence-based practice in pediatric pharmacology.